Global and North America Human Growth Hormone Market

Human Growth Hormone Comprehensive Study by Type (Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (rhGH)), Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others) Players and Region - Global Market Outlook to 2030

Human Growth Hormone Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.73%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Human Growth Hormone
Human Growth Hormone (HGH) stimulates growth, cell production and regeneration of human cells. It is produced by pituitary gland and helps in regulate body composition, body fluids, muscles and bone growth. The side effects of HGH include fluid retention, joint and muscle pain. Moreover, it has been banned by Food and Drug Administration (FDA) as well as International Olympic Committee.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR6.73%


The market is fragmented with numerous players focusing on technique and quality of the product due to which the global industrial silica sand market can witness an upsurge in the forecast period. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Human Growth Hormone market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Eli Lilly and Company [United States], Ferring Holding SA [Switzerland], Genentech [United States], Merck & Co. [United States], Novo Nordisk [Denmark], Pfizer [United States], Sandoz International GmbH [Germany] and Ipsen [France] are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Teva Pharmaceutical Industries [Israel], EMD Serono Inc [United States], Roche Holding AG [Switzerland], EMD Serono Inc [United States] and GeneScience Pharmaceuticals [China].

Segmentation Overview
AMA Research has segmented the market of Global Human Growth Hormone market by Type (Recombinant Human Growth Hormone (rhGH) and Human Growth Hormone (rhGH)), Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age and Others) and Region.



On the basis of geography, the market of Human Growth Hormone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023.

Influencing Trend:
Growing Use for the Patients with Chronic Renal Failure and Growing Customized Drug Use For Medical Purpose

Market Growth Drivers:
Growing Adoption of Growth Hormone Drugs for Medical Purpose and Rising Incidences of Chronic Disease among Children and Adults

Challenges:
Rising Illicit Use of Drugs and Lack of Awareness in Emerging Countries

Restraints:
Adverse Effect Associated with Human Growth Hormone and Stringent Regulatory Guidelines Regarding its Use

Opportunities:
Growing Awareness About its Use in Emerging Countries

Market Leaders and their expansionary development strategies
In Janaury 2024, Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has added three new endocrinology therapies to its specialist portfolio, following an exclusive distribution agreement with Danish company Ascendis Pharma A/S
In August 2023, NGENLA is expected to become available for U.S. prescribing Growth hormone deficiency (GHD) is a rare disease characterized by the inadequate secretion of the growth hormone somatropin from the pituitary gland, affecting one in approximately 4,000 to 10,000 children.
HGH is made illegal by Food and Administration. Though, it is allowed to be used in few specific medical conditions. Additionally, it has been banned by most professional sports leagues in the United States and by the International Olympic Committee

Key Target Audience
HGH Drug Providers, Research Institutes, Government Agencies and Potential Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Recombinant Human Growth Hormone (rhGH)
  • Human Growth Hormone (rhGH)
By Application
  • Growth Hormone Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Small for Gestational Age
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Adoption of Growth Hormone Drugs for Medical Purpose
      • 3.2.2. Rising Incidences of Chronic Disease among Children and Adults
    • 3.3. Market Challenges
      • 3.3.1. Rising Illicit Use of Drugs
      • 3.3.2. Lack of Awareness in Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Growing Use for the Patients with Chronic Renal Failure
      • 3.4.2. Growing Customized Drug Use For Medical Purpose
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Growth Hormone, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Growth Hormone (Value)
      • 5.2.1. Global Human Growth Hormone by: Type (Value)
        • 5.2.1.1. Recombinant Human Growth Hormone (rhGH)
        • 5.2.1.2. Human Growth Hormone (rhGH)
      • 5.2.2. Global Human Growth Hormone by: Application (Value)
        • 5.2.2.1. Growth Hormone Deficiency
        • 5.2.2.2. Turner Syndrome
        • 5.2.2.3. Idiopathic Short Stature
        • 5.2.2.4. Prader-Willi Syndrome
        • 5.2.2.5. Small for Gestational Age
        • 5.2.2.6. Others
      • 5.2.3. Global Human Growth Hormone Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Human Growth Hormone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company [United States]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ferring Holding SA [Switzerland]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genentech [United States]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. [United States]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk [Denmark]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer [United States]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sandoz International GmbH [Germany]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ipsen [France]
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Human Growth Hormone Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Growth Hormone (Value)
      • 7.2.1. Global Human Growth Hormone by: Type (Value)
        • 7.2.1.1. Recombinant Human Growth Hormone (rhGH)
        • 7.2.1.2. Human Growth Hormone (rhGH)
      • 7.2.2. Global Human Growth Hormone by: Application (Value)
        • 7.2.2.1. Growth Hormone Deficiency
        • 7.2.2.2. Turner Syndrome
        • 7.2.2.3. Idiopathic Short Stature
        • 7.2.2.4. Prader-Willi Syndrome
        • 7.2.2.5. Small for Gestational Age
        • 7.2.2.6. Others
      • 7.2.3. Global Human Growth Hormone Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Growth Hormone: by Type(USD Million)
  • Table 2. Human Growth Hormone Recombinant Human Growth Hormone (rhGH) , by Region USD Million (2018-2023)
  • Table 3. Human Growth Hormone Human Growth Hormone (rhGH) , by Region USD Million (2018-2023)
  • Table 4. Human Growth Hormone: by Application(USD Million)
  • Table 5. Human Growth Hormone Growth Hormone Deficiency , by Region USD Million (2018-2023)
  • Table 6. Human Growth Hormone Turner Syndrome , by Region USD Million (2018-2023)
  • Table 7. Human Growth Hormone Idiopathic Short Stature , by Region USD Million (2018-2023)
  • Table 8. Human Growth Hormone Prader-Willi Syndrome , by Region USD Million (2018-2023)
  • Table 9. Human Growth Hormone Small for Gestational Age , by Region USD Million (2018-2023)
  • Table 10. Human Growth Hormone Others , by Region USD Million (2018-2023)
  • Table 11. South America Human Growth Hormone, by Country USD Million (2018-2023)
  • Table 12. South America Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 13. South America Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 14. Brazil Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 15. Brazil Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 16. Argentina Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 17. Argentina Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 20. Asia Pacific Human Growth Hormone, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 22. Asia Pacific Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 23. China Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 24. China Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 25. Japan Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 26. Japan Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 27. India Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 28. India Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 29. South Korea Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 30. South Korea Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 31. Taiwan Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 32. Taiwan Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 33. Australia Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 34. Australia Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 37. Europe Human Growth Hormone, by Country USD Million (2018-2023)
  • Table 38. Europe Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 39. Europe Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 40. Germany Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 41. Germany Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 42. France Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 43. France Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 44. Italy Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 45. Italy Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 47. United Kingdom Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 48. Netherlands Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 49. Netherlands Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 51. Rest of Europe Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 52. MEA Human Growth Hormone, by Country USD Million (2018-2023)
  • Table 53. MEA Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 54. MEA Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 55. Middle East Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 56. Middle East Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 57. Africa Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 58. Africa Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 59. North America Human Growth Hormone, by Country USD Million (2018-2023)
  • Table 60. North America Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 61. North America Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 62. United States Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 63. United States Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 64. Canada Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 65. Canada Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 66. Mexico Human Growth Hormone, by Type USD Million (2018-2023)
  • Table 67. Mexico Human Growth Hormone, by Application USD Million (2018-2023)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Human Growth Hormone: by Type(USD Million)
  • Table 77. Human Growth Hormone Recombinant Human Growth Hormone (rhGH) , by Region USD Million (2025-2030)
  • Table 78. Human Growth Hormone Human Growth Hormone (rhGH) , by Region USD Million (2025-2030)
  • Table 79. Human Growth Hormone: by Application(USD Million)
  • Table 80. Human Growth Hormone Growth Hormone Deficiency , by Region USD Million (2025-2030)
  • Table 81. Human Growth Hormone Turner Syndrome , by Region USD Million (2025-2030)
  • Table 82. Human Growth Hormone Idiopathic Short Stature , by Region USD Million (2025-2030)
  • Table 83. Human Growth Hormone Prader-Willi Syndrome , by Region USD Million (2025-2030)
  • Table 84. Human Growth Hormone Small for Gestational Age , by Region USD Million (2025-2030)
  • Table 85. Human Growth Hormone Others , by Region USD Million (2025-2030)
  • Table 86. South America Human Growth Hormone, by Country USD Million (2025-2030)
  • Table 87. South America Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 88. South America Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 89. Brazil Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 90. Brazil Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 91. Argentina Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 92. Argentina Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 93. Rest of South America Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 94. Rest of South America Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 95. Asia Pacific Human Growth Hormone, by Country USD Million (2025-2030)
  • Table 96. Asia Pacific Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 97. Asia Pacific Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 98. China Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 99. China Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 100. Japan Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 101. Japan Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 102. India Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 103. India Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 104. South Korea Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 105. South Korea Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 106. Taiwan Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 107. Taiwan Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 108. Australia Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 109. Australia Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 110. Rest of Asia-Pacific Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 111. Rest of Asia-Pacific Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 112. Europe Human Growth Hormone, by Country USD Million (2025-2030)
  • Table 113. Europe Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 114. Europe Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 115. Germany Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 116. Germany Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 117. France Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 118. France Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 119. Italy Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 120. Italy Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 121. United Kingdom Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 122. United Kingdom Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 123. Netherlands Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 124. Netherlands Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 125. Rest of Europe Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 126. Rest of Europe Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 127. MEA Human Growth Hormone, by Country USD Million (2025-2030)
  • Table 128. MEA Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 129. MEA Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 130. Middle East Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 131. Middle East Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 132. Africa Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 133. Africa Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 134. North America Human Growth Hormone, by Country USD Million (2025-2030)
  • Table 135. North America Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 136. North America Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 137. United States Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 138. United States Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 139. Canada Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 140. Canada Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 141. Mexico Human Growth Hormone, by Type USD Million (2025-2030)
  • Table 142. Mexico Human Growth Hormone, by Application USD Million (2025-2030)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Growth Hormone: by Type USD Million (2018-2023)
  • Figure 5. Global Human Growth Hormone: by Application USD Million (2018-2023)
  • Figure 6. South America Human Growth Hormone Share (%), by Country
  • Figure 7. Asia Pacific Human Growth Hormone Share (%), by Country
  • Figure 8. Europe Human Growth Hormone Share (%), by Country
  • Figure 9. MEA Human Growth Hormone Share (%), by Country
  • Figure 10. North America Human Growth Hormone Share (%), by Country
  • Figure 11. Global Human Growth Hormone share by Players 2023 (%)
  • Figure 12. Global Human Growth Hormone share by Players (Top 3) 2023(%)
  • Figure 13. Global Human Growth Hormone share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Eli Lilly and Company [United States] Revenue, Net Income and Gross profit
  • Figure 16. Eli Lilly and Company [United States] Revenue: by Geography 2023
  • Figure 17. Ferring Holding SA [Switzerland] Revenue, Net Income and Gross profit
  • Figure 18. Ferring Holding SA [Switzerland] Revenue: by Geography 2023
  • Figure 19. Genentech [United States] Revenue, Net Income and Gross profit
  • Figure 20. Genentech [United States] Revenue: by Geography 2023
  • Figure 21. Merck & Co. [United States] Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. [United States] Revenue: by Geography 2023
  • Figure 23. Novo Nordisk [Denmark] Revenue, Net Income and Gross profit
  • Figure 24. Novo Nordisk [Denmark] Revenue: by Geography 2023
  • Figure 25. Pfizer [United States] Revenue, Net Income and Gross profit
  • Figure 26. Pfizer [United States] Revenue: by Geography 2023
  • Figure 27. Sandoz International GmbH [Germany] Revenue, Net Income and Gross profit
  • Figure 28. Sandoz International GmbH [Germany] Revenue: by Geography 2023
  • Figure 29. Ipsen [France] Revenue, Net Income and Gross profit
  • Figure 30. Ipsen [France] Revenue: by Geography 2023
  • Figure 31. Global Human Growth Hormone: by Type USD Million (2025-2030)
  • Figure 32. Global Human Growth Hormone: by Application USD Million (2025-2030)
  • Figure 33. South America Human Growth Hormone Share (%), by Country
  • Figure 34. Asia Pacific Human Growth Hormone Share (%), by Country
  • Figure 35. Europe Human Growth Hormone Share (%), by Country
  • Figure 36. MEA Human Growth Hormone Share (%), by Country
  • Figure 37. North America Human Growth Hormone Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli Lilly and Company [United States]
  • Ferring Holding SA [Switzerland]
  • Genentech [United States]
  • Merck & Co. [United States]
  • Novo Nordisk [Denmark]
  • Pfizer [United States]
  • Sandoz International GmbH [Germany]
  • Ipsen [France]
Additional players considered in the study are as follows:
Teva Pharmaceutical Industries [Israel] , EMD Serono Inc [United States] , Roche Holding AG [Switzerland] , EMD Serono Inc [United States] , GeneScience Pharmaceuticals [China]
Select User Access Type

Key Highlights of Report


Mar 2024 248 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and North America Human Growth Hormone Market Quantitative research analysis
Global and North America Human Growth Hormone Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Eli Lilly and Company [United States], Ferring Holding SA [Switzerland], Genentech [United States], Merck & Co. [United States], Novo Nordisk [Denmark], Pfizer [United States], Sandoz International GmbH [Germany] and Ipsen [France] etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Use for the Patients with Chronic Renal Failure " is seen as one of major influencing trends for Human Growth Hormone Market during projected period 2023-2030.
The Human Growth Hormone market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global and North America Human Growth Hormone Market Report?

Have a Query? Click Here

Other Related Reports

Endobronchial Ultrasound Biopsy Comprehensive Study by Type (Biopsy Forceps, Cytology Brushes, Biopsy Needles, Transbronchial Aspiration Needles, Spray Catheters, Others), Application (Infection Diag...
$ 3650
Chamomile Oil Comprehensive Study by Type (High-Quality, Middle-Quality, Low-Quality), Application (Essential Oils, Other), Nature (Organic Chamomile Essential Oil, Conventional Chamomile Essential O...
$ 3450
Drugs of Abuse Testing Comprehensive Study by Type (Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers), Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devi...
$ 3750
Sterilization Monitoring Comprehensive Study by Type (Biological Indicators, Chemical Indicators), Application (Hospitals, Pharmaceutical, Biotechnology, and Medical Device Companies, Research and Ac...
$ 3800
Retail Clinics Comprehensive Study by Type (Hospital-owned Retail Clinics, Retail-owned Retail Clinics), Application (Clinical Chemistry & Immunoassay, Point of Care Diagnostics, Others), Distributio...
$ 3500
Dental Drug Comprehensive Study by Type (Injectable, Oral, Spray), Application (Drug stores, Retail pharmacies, Hospital pharmacies, Online stores) Players and Region - Global Market Outlook to 2026
$ 3500